TY  - JOUR
AU  - Carpio, D
AU  - Jauregui-Amezaga, A
AU  - de Francisco, R
AU  - de Castro, L
AU  - Barreiro-de Acosta, M
AU  - Mendoza, J L
AU  - Mañosa, M
AU  - Ollero, V
AU  - Castro, B
AU  - González-Conde, B
AU  - Hervías, D
AU  - Sierra Ausin, M
AU  - Sancho Del Val, L
AU  - Botella-Mateu, B
AU  - Martínez-Cadilla, J
AU  - Calvo, M
AU  - Chaparro, M
AU  - Ginard, D
AU  - Guerra, I
AU  - Maroto, N
AU  - Calvet, X
AU  - Fernández-Salgado, E
AU  - Gordillo, J
AU  - Rojas Feria, M
AU  - GETECCU
PY  - 2016
DO  - 10.1093/ecco-jcc/jjw022
UR  - http://hdl.handle.net/10668/9762
T2  - Journal of Crohn's & colitis
AB  - Despite having adopted preventive measures, tuberculosis (TB) may still occur in patients with inflammatory bowel disease (IBD) treated with anti-tumour necrosis factor (anti-TNF). Data on the causes and characteristics of TB cases in this scenario...
LA  - en
KW  - Anti-TNF
KW  - Crohn’s disease
KW  - adalimumab
KW  - inflammatory bowel disease
KW  - infliximab
KW  - prevention
KW  - retreatment
KW  - tuberculosis
KW  - ulcerative colitis
KW  - Adalimumab
KW  - Adult
KW  - Female
KW  - Follow-Up Studies
KW  - Guideline Adherence
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Inflammatory Bowel Diseases
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Opportunistic Infections
KW  - Practice Guidelines as Topic
KW  - Retreatment
KW  - Retrospective Studies
KW  - Spain
KW  - Treatment Outcome
KW  - Tuberculin Test
KW  - Tuberculosis
TI  - Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
TY  - research article
VL  - 10
ER  -